Fate Therapeutics, Inc.FATENASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

30 analysts·High coverage

53%

Rating Distribution

Strong Buy

00%

Buy

1653%

Hold

1240%

Sell

27%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 3073% higher.

Bear Case

$3.00

+141%

Consensus

$39.50

+3073%

Bull Case

$145.00

+11547%

Price Range30 analysts

Low

Consensus

High

$3.00

$145.00

Current Target

Current Price

$1.25

Upside to Target

$38.26

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.16(9 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+23.85%

EPS—

FY2028

Rev-3.32%

EPS—

FY2029

Rev+1029.77%

EPS—

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+21.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 6, 2025Stifel Nicolaus

Fate Therapeutics price target lowered to $3 from $5 at Stifel

Target:$3.00

+188.5%from $1.04

Nov 13, 2024BMO Capital

Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital

Target:$5.00

+48.4%from $3.37

Aug 14, 2024Stifel Nicolaus

Fate Therapeutics (FATE) PT Lowered to $5 at Stifel

Target:$5.00

+52.9%from $3.27

Jun 17, 2024Piper Sandler

Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight

Target:$6.00

+66.4%from $3.60

May 16, 2024H.C. Wainwright

Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright

Target:$5.00

+17.9%from $4.24

May 10, 2024Piper Sandler

Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler

Target:$4.00

+3.1%from $3.88

May 10, 2024BMO Capital

Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital

Target:$6.00

+55.2%from $3.87

May 10, 2024Canaccord Genuity

Fate Therapeutics price target lowered to $9 from $11 at Canaccord

Target:$9.00

+130.8%from $3.90

Jan 9, 2023Goldman Sachs

Goldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4

Target:$4.00

-9.1%from $4.40

Jan 6, 2023Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8

Target:$8.00

+89.6%from $4.22

Jan 6, 2023Piper Sandler

Piper Sandler Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $12

Target:$12.00

+9.1%from $11.00

Jan 6, 2023BMO Capital

BMO Capital Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $7

Target:$7.00

-36.4%from $11.00

Jan 5, 2023Truist Financial

Fate Therapeutics downgraded to Hold from Buy at Truist

Target:$7.00

-36.4%from $11.00

Dec 15, 2022Goldman Sachs

Fate Therapeutics initiated with a Sell at Goldman Sachs

Target:$10.00

-34.9%from $15.37

Dec 13, 2022Truist Financial

Truist Securities Maintains Buy on Fate Therapeutics, Lowers Price Target to $46

Target:$46.00

+197.6%from $15.46

Dec 13, 2021Oppenheimer

Fate lymphoma update should erase concerns, says Oppenheimer

Target:$135.00

+175.6%from $48.98

Nov 8, 2021Citigroup

Fate Therapeutics upgraded to Buy from Neutral at Citi

Target:$87.00

+43.1%from $60.79

Nov 5, 2021Roth Capital

Fate Therapeutics price target lowered to $60 from $90 at Roth Capital

Target:$60.00

-2.3%from $61.42

Oct 25, 2021Jefferies

Jefferies Stick to Their Buy Rating for Fate Therapeutics

Target:$145.00

+149.3%from $58.16

Aug 20, 2021Piper Sandler

Fate Therapeutics selloff on data a buying opportunity, says Piper Sandler

Target:$113.00

+68.6%from $67.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance